乙肝转阴散对HepG2.2.15细胞HBsAg和HBeAg的抑制作用

目的 :研究乙肝转阴散(YGZYS)对HepG2.2.15细胞乙型肝炎表面抗原(HBsAg)和乙型肝炎E抗原(HBeAg)分泌的影响。 方法 :采用四甲基噻唑蓝(MTT)法检测YGZYS对HepG2.2.15细胞的半数毒性浓度(TC₅₀)和最大无毒浓度(TC₀);在TC₀基础上观察药物5个不同浓度作用于HepG2.2.15细胞,采用酶联免疫吸附法(ELISA)测定培养4 d和8 d的细胞上清液HBsAg和HBeAg的滴度。 结果 :TC₅₀ 5.386 g ·L^-1,TC₀ 0.736 g ·L^-1。提示YGZYS对HepG2.2.15细胞毒性作用较低。在无毒浓度下,YGZYS能有效地抑制HepG2.2.15细胞分泌HBsAg和HBeAg;且治疗指数(TI)均大于2,说明YGZYS为高效低毒的抗HBV药物。 结论 :YGZYS可有效地抑制HepG2.2.15细胞HBsAg和HBeAg的分泌,且毒性较低。

Inhibitory Effect of Yigan Zhuanyin San on HBsAg and HBeAg in HepG2.2.15 Cell

Objective: To study the effect of traditional Chinese medicine Yigan Zhuanyin San (YGZYS) on HBsAg and HBeAg of HepG2.2.15 cell. Method: The TC₅₀ and TC₀ of YGZYS to the HepG2.2.15 cell were determined by MTT assay. At non-toxic range of concentration, five different concentrations of YGZYS were added respectively to HepG2.2.15 cells. At 4d and 8d after treatment with drugs, the supernatant of HepG2.2.15 were collected for determining the levels of HBsAg and HBeAg by ELISA. Result: TC₅₀ 5.386 g ·L^-1, TC₀ 0.736 g ·L^-1. YGZYS had little cellulotoxicity. YGZYS at the largest non-cellulotoxic concentration could suppress HBsAg and HBeAg expression in HepG2.2.15 cell, and the therapeutic index (TI)>2, YGZYS appeared to be an effective and low toxic anti-HBV drug. Conclusion: YGZYS can suppress HBsAg and HBeAg expression in HepG2.2.15 cell, and is a lower toxic drug.